*Organization & Developments: Geron (Archives 2010 - 2016)

Parents

2010: Geron Initiates First Spinal Cord Clinical Trial of Human Embryonic Stem Cell-Based Therapy (2010)
2011: First test of human embryonic stem cell therapy in people discontinued (2011)
2011: Stem cell trailblazer Geron dumped its stem cell therapy intellectual property, including a program to treat spinal cord injury. (2011)
2014: Here's Why Geron Has Been So Volatile This Year (GERN)
2014: In Its Bumpy Second Life, Geron Signs Top Drug Over to J&J for up to $900 million in Milestone Payments
2014: J&J bets up to $935M that Geron's drug can shake a checkered past
2015: Geron Corp (GERN) Announces Receipt of FDA Orphan Drug Designation for Imetelstat as Myelofibrosis Treatment_www.streetinsider.com
2015: Investing In Johnson & Johnson's Pharmaceutical Collaborations Can Provide Dramatic Returns - Johnson & Johnson (NYSE:JNJ)
2016: As I Predicted, Cash-Rich Geron Optimizes Dosage In Myelofibrosis Trial - Geron Corporation (NASDAQ:GERN)
2016: Geron Corporation Exploded 49% Higher in 2015
2016: Geron: Announcing Imetelstat Patent Protection Through 2032 - Geron Corporation (NASDAQ:GERN)
2016: Geron: Promising Signs - Geron Corporation (NASDAQ:GERN)
2016: Geron: What To Expect From Imetelstat Now - Geron Corporation (NASDAQ:GERN)